What impact will CVS Health’s decision to exclude Zepbound from its formulary have on patient access? How are pricing strategies influencing competition between Zepbound and Wegovy? What factors have contributed to the rising popularity of GLP-1 receptor agonists?
Eli Lilly’s stock wobbled Thursday after a looming coverage hit was detailed for its blockbuster weight-loss drug Zepbound. CVS Health announced that the drugs Wegovy and Saxenda from rival drugmaker Novo Nordisk will become the preferred options on its standard formulary, or list of covered drugs, as of July 1. Zepbound will be excluded.
This could complicate access to a drug that many patients cannot afford to pay for on their own. The formulary is maintained by CVS Health’s pharmacy benefits management business, which runs prescription drug coverage for millions of people. Employers and insurers—who pay most of the prescription bill—use the formulary to decide which drugs get coverage.
They can customize their coverage plans to include Zepbound. However, CVS Health spokesman David Whitrap stated that most employers wind up using the standard formulary because of the discounts negotiated for them.
Patients taking Zepbound will be able to switch to Wegovy if the Lilly drug is excluded from their coverage, Whitrap added. CVS Health will also start selling Wegovy at a discounted price of about $500 monthly at thousands of drugstores for people without coverage. Novo had announced its new lower price last month.
Wegovy and Zepbound are part of a wave of obesity medications known as GLP-1 receptor agonists that have soared in popularity due to the amount of weight people lose while taking the injections. Coverage of these drugs has been uneven, in part due to their cost and the large number of patients who could benefit from them.
Shortages of the drugs have also made access challenging, but those have eased recently. This allows pharmacy benefit managers to pit the products against each other to negotiate lower prices for inclusion on a formulary.
Lilly may have to make some price cuts to restore formulary access, said Daniel Barasa, who follows the company for Gabelli Funds. However, he believes big employers will still include both treatments on their lists of covered drugs, leaving the choice to patients and doctors.
Lilly mentioned that a head-to-head study of the two drugs showed that Zepbound helped patients drop more pounds. Zepbound has emerged as one of Lilly’s top sellers, with sales jumping to $2.3 billion in the recently completed first quarter, up from $517 million a year ago during the drug’s first full quarter on the market.
Lilly shares shed more than $90 in value, falling nearly 11% to $804.06 Thursday afternoon, while broader indexes rose slightly.
Lilly’s Weight-Loss Drug Zepbound Faces Coverage Challenges from CVS Health
Amidst the rising interest in weight-loss medications, Eli Lilly’s Zepbound is creating a significant buzz in the pharmaceutical industry. However, while the drug shows considerable promise for aiding weight loss, it is not immune to the challenges surrounding insurance coverage, particularly from major players like CVS Health. This article explores the implications of these coverage hurdles, the potential of Zepbound, and the larger context of weight-loss treatments in today’s healthcare landscape.
The Promise of Zepbound
Zepbound (also known as tirzepatide) was approved by the FDA for weight management in adults with obesity or certain weight-related conditions. Its mechanism is rooted in mimicking two hormones, GLP-1 and GIP, which play critical roles in appetite regulation and glucose metabolism. Clinical trials have demonstrated significant weight loss for individuals taking the drug, making it one of the first treatments that can effectively help patients achieve meaningful weight loss outcomes.
Given the prevalence of obesity and related health conditions, Zepbound has the potential to be a transformative option for many individuals seeking assistance in managing their weight. For the healthcare system, effective weight management tools could mean a reduction in obesity-related complications such as diabetes, heart disease, and certain cancers.
Coverage Challenges from CVS Health
However, the road to widespread adoption is fraught with potential barriers. One of the most significant challenges is insurance coverage. CVS Health, one of the largest pharmacy benefit managers (PBMs) in the U.S., plays a critical role in determining which drugs are covered under their plans. The decision by CVS to limit coverage or impose high out-of-pocket costs for Zepbound could significantly affect patient access to the medication.
Recent reports indicate that CVS Health has initiated measures that could restrict access to Zepbound, as well as other weight-loss medications. These measures include requiring prior authorization—a process that necessitates healthcare providers to provide extensive documentation justifying the use of Zepbound before coverage is granted. Additionally, CVS may set higher copays for weight-loss drugs compared to other medications, influencing patients’ decision to pursue treatment.
Pharmaceutical companies often negotiate with PBMs to secure coverage for their medications; however, the power wielded by large PBMs like CVS Health complicates this landscape. By prioritizing cost-saving strategies, CVS may be responding to pressure from employers and health insurers to manage escalating drug costs. Unfortunately, such policies may discount the broader implications of obesity on healthcare expenses, possibly leading to a situation where patients forgo necessary treatment due to affordability issues.
Implications for Patients
The complications arising from CVS Health’s decision-making can significantly impact individuals who could benefit from Zepbound. For many patients, the need for prior authorization can delay treatment and add stress to an already challenging process. The emphasis on cost containment often leads to confusion and frustration among patients seeking effective treatment options.
Moreover, those with lower financial means could find it particularly challenging to navigate these barriers. In a healthcare system increasingly defined by access issues, the challenges surrounding coverage for Zepbound could further stratify access to essential treatments based on socio-economic status.
The Landscape of Weight-Loss Medications
The ongoing debate regarding Zepbound’s coverage also highlights a broader issue within the realm of weight-loss medications. Several new treatments are emerging on the market, but many come with premium price tags. The public interest in these treatments has surged, yet navigability through the insurance landscape remains a significant hurdle.
Healthcare providers may find themselves in a precarious situation, as they aim to offer the best treatment options while confronting the limitations imposed by insurance policies. This tension between innovative medical advancements and restrictive coverage practices creates a complex environment for healthcare delivery.
Future Outlook
The future for Zepbound and similar weight-loss medications will likely depend on both market dynamics and advocacy efforts. As the importance of addressing obesity and its comorbid conditions becomes increasingly recognized, there may be growing pressure on PBMs to offer fair access to these medications. Advocacy groups and healthcare providers will likely need to push for more transparent and equitable policies to ensure that effective treatments reach those in need.
Additionally, as more data concerning the long-term effectiveness and safety of Zepbound becomes available, it may influence coverage decisions. If the drug demonstrably reduces healthcare costs associated with obesity-related ailments, it may prompt a re-evaluation of its pricing and accessibility.
Conclusion
In summary, while Eli Lilly’s Zepbound shows potential as a valuable tool in the fight against obesity, its coverage challenges, especially in relation to CVS Health, raise important questions about accessibility and affordability in the current healthcare landscape. Navigating insurance policies will be crucial for both patients and healthcare providers in harnessing the benefits of this groundbreaking treatment. As the dialogue surrounding weight management and pharmacoeconomics continues to evolve, stakeholders must work collaboratively to ensure that advancements in treatment are matched by equally progressive approaches to access and coverage.
Eli Lilly’s weight-loss drug, Zepbound, is facing a significant coverage challenge as CVS Health announced it will exclude Zepbound from its standard drug formulary starting July 1, 2025. This decision favors competitor Novo Nordisk’s drugs, Wegovy and Saxenda, potentially limiting patient access to Zepbound, which many rely on for affordability through prescription coverage. (apnews.com)
In response to this exclusion, CVS Health plans to offer Wegovy at a discounted price of approximately $500 monthly for uninsured customers. Despite Zepbound’s sales reaching $2.3 billion in the first quarter of 2025, up from $517 million a year earlier, the company’s shares declined nearly 11% following CVS’s announcement. (apnews.com)
Analysts suggest that the exclusion may prompt price adjustments for Zepbound. However, large employers are expected to continue offering choices between Zepbound and Wegovy, depending on physician and patient preferences. The rising popularity of GLP-1 receptor agonists like Zepbound and Wegovy is attributed to their significant weight loss results, though high costs and initial shortages have previously limited access. (apnews.com)
This development underscores the complexities patients face in accessing effective weight-loss treatments, highlighting the need for consistent insurance coverage and affordability.
CVS Health Excludes Zepbound from Coverage, Impacting Eli Lilly:
- Lilly star weight-loss drug Zepbound faces coverage challenge from CVS Health
- Eli Lilly’s strong quarter undercut by CVS move to drop Zepbound coverage